Figure 2.
Figure 2. Overall survival of 90 eligible patients with stages II to IV follicular non-Hodgkin lymphoma treated with 6 cycles of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab.

Overall survival of 90 eligible patients with stages II to IV follicular non-Hodgkin lymphoma treated with 6 cycles of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal